CoChat

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Open access
Badar, Talha, Atallah, Ehab, Shallis, Rory, Saliba, Antoine N., Patel, Anand, Bewersdorf, Jan P., Grenet, Justin, Stahl, Maximilian, Duvall, Adam, Burkart, Madelyn, Palmisiano, Neil, Bradshaw, Danielle, Kubiak, Michal, Dinner, Shira, Goldberg, Aaron D., Abaza, Yasmin, Murthy, Guru Subramanian Guru, Kota, Vamsi, Litzow, Mark R. · 2023 · Leukemia
Cited by 65

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

We conducted a multi-center study to analyze factors predicting survival among patients with TP53-mutated (m) AML receiving allogeneic hematopoietic stem cell transplant (allo-HSCT) in the recent era. Out of 370 TP53m AML patients, 68 (18%) patients were bridged to allo-HSCT. The median age of the patients was 63 years (range, 33–75), 82% of patients had complex cytogenetics and 66% of patients had multi-hit TP53m. Forty three percent received myeloablative conditioning and 57% received reduced intensity conditioning. The incidence of acute graft versus host disease (GVHD) was 37% and chronic GVHD was 44%. The median event-free survival (EFS) from the time of allo-HSCT was 12.4 months (95% CI: 6.24–18.55) and median overall survival (OS) was 24.5 months (95% CI: 21.80–27.25). In multivariate analysis utilizing variables that showed significance in univariate analysis, complete remission at day 100 post allo-HSCT retained significance for EFS (HR: 0.24, 95% CI: 0.10–0.57, p = 0.001) and OS (HR: 0.22, 95% CI: 0.10–0.50, p ≤ 0.001). Similarly, occurrence of chronic GVHD retained significance for EFS (HR: 0.21, 95% CI: 0.09–0.46, p ≤ 0.001) and OS (HR: 0.34, 95% CI: 0.15–0.75, p = 0.007). Our report suggests that allo-HSCT offers the best opportunity to improve long-term outcome among patients with TP53m AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-023-01847-7

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 65

Metadata

Authors
Badar, T., Atallah, E., Shallis, R., Saliba, A. N., Patel, A., Bewersdorf, J. P., Grenet, J., Stahl, M., Duvall, A., Burkart, M., Palmisiano, N., Bradshaw, D., Kubiak, M., Dinner, S., Goldberg, A. D., Abaza, Y., Murthy, G. S. G., Kota, V., & Litzow, M. R.
Venue
Leukemia
Published
2023-02-18
Volume
37
Issue
4
Pages
799-806
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W4321329196
Cited by
65
References
11
FWCI
11.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). https://app.cochat.ai/papers/10.1038/s41375-023-01847-7
The paper
Badar, T., Atallah, E., Shallis, R., Saliba, A. N., Patel, A., Bewersdorf, J. P., Grenet, J., Stahl, M., Duvall, A., Burkart, M., Palmisiano, N., Bradshaw, D., Kubiak, M., Dinner, S., Goldberg, A. D., Abaza, Y., Murthy, G. S. G., Kota, V., & Litzow, M. R. (2023). Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. https://doi.org/10.1038/s41375-023-01847-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.